×

公司新聞

康龍化成完成對聯斯達的戰略投資 并與聯斯達建立戰略合作關系
作者:LINKSTART  |   發布時間:2020-07-27 10:17  |   瀏覽次數:0  |  

Pharmaron Completes Strategic Investment in LinkStart

and Enters into Strategic Partnership Arrangement

 

Beijing, China, June 18,2019 — Pharmaron, a global leading life science services company headquartered in Beijing, and LinkStart SMO Ltd. (LinkStart), a clinical SMO headquartered in Beijing, announced today that Pharmaron completed a strategic investment and entered into a strategic partnership arrangement with LinkStart, aiming for a sustainable and deep strategic relationship.

 

LinkStart will become Pharmaron’s strategic partner for clinical development services in China. Both parties will make full use of their complementary strengths in technologies, resources and market access to better serve their partners in the clinical development area. This partnership strengthens Pharmaron’s clinical development service capabilities, which follows the acquisition of its clinical pharmacology center in Baltimore, Maryland in 2017 and the recent acquisition of a majority stake in CR Medicon. This investment facilitates the construction of the end-to-end service platform to support needs from drug discovery through to clinical development and accelerate the clinical development process.  

 

Mr. Yang Liu, founder, Chairman and CEO of LinkStart, expressed his enthusiasm about this partnership. “LinkStart has been striving to provide high quality clinical SMO services to our partners, in addition to elevating the SMO industry’s standard in China by working closely with clinically relevant parties. We are excited to have Pharmaron, a highly experienced global player in the life science service industry, as our strategic investor and partner. With this strategic partnership, my team and I are confident to realize LinkStart’s long-term strategy, to better serve the life science industry by accelerating the clinical development process for innovative medicines and to become a world-renowned SMO brand.” 

 

Mr. Larry Lou, President and COO of Pharmaron commented, “Our investment in LinkStart strengthens Pharmaron’s clinical development capabilities, which allows Pharmaron to be a step closer to providing fully integrated drug R&D service to our partners. This clinical SMO investment complements our recent strategic move with CR Medicon and together with our clinical pharmacology center and clinical metabolism labs in the USA and UK, we can better support our partners’ clinical development needs both domestically and globally.”

 

   

About LinkStart

LinkStart is a privately owned, leading clinical SMO in China. Founded in 2012, headquartered in Beijing, LinkStart has established stable and long term collaboration relationship with over 500 national clinical research centers in China. It has a branch in Nanjing, and business offices in Shanghai, Nanjing, Guangzhou, Hangzhou, Chengdu, Haerbin, Hefei, Wuhan, Xi’an, etc, covering 110+ cities in China. The company has conducted 400+ studies, of which 85% are the 1stclass of new drugs and biological products. LinkStart is particularly experienced in conducting clinical research for drugs against cancer, endocrinological diseases, cardiovascular diseases, infection and immune rheumatoid diseases.    

 

About Pharmaron 

Pharmaron (China’s A-share Market: 300759) is a public-owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, chemical & pharmaceutical development to clinical CRO. With over 6,800 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. 

www.pharmaron.com

  

康龍化成完成對聯斯達的戰略投資

并與聯斯達建立戰略合作關系

 

中國,北京,2019年6月18日康龍化成宣布戰略性投資北京聯斯達醫藥科技發展有限公司(提供第三方獨立臨床研究現場管理服務SMO,總部位于北京,英文名:LinkStart SMO Ltd.以下簡稱聯斯達),并建立戰略合作關系,致力于可持續發展及深層次的合作。

 

通過此次聯手,聯斯達將成為康龍化成臨床開發服務領域的戰略合作伙伴,雙方將充分發揮各自技術、資源及市場方面的優勢,為客戶提供更加優良的臨床開發服務。 這是康龍化成繼2017年收購美國馬里蘭州巴爾的摩臨床藥理中心(CPC,以及近期取得南京希麥迪(立足于中國市場的臨床CRO公司)控股權之后,在增強臨床服務能力方面的又一布局。此舉將進一步完善公司的臨床開發服務平臺,豐富公司一體化藥物研發服務內容,加快藥物臨床開發進程。

 

聯斯達創始人、董事長兼CEO劉洋先生對該戰略合作表示非常期待:“聯斯達一直致力于為合作伙伴提供高質量的臨床SMO服務,與業界臨床相關機構保持密切合作關系,共同提升中國SMO行業水準。我們很高興有康龍化成這樣一家在國際生命科學研發服務領域具有豐富經驗的企業作為我們的投資人及戰略合作伙伴。我和團隊將更有信心實現聯斯達的長遠戰略目標,服務于生命科學產業,加快創新藥的臨床開發進程,打造中國SMO的世界品牌?!?/span>

            

    康龍化成總裁兼COO樓小強先生表示:“通過投資聯斯達并建立戰略合作關系,我們的臨床開發服務能力得到進一步延伸和提高,進一步豐富和夯實了我們的全流程、一體化研發服務平臺。此次針對臨床SMO服務的投資,是繼近期追加投資希麥迪之后的系列舉措之一,結合我們的臨床藥理中心,以及英美兩地的臨床代謝試驗室,我們有信心為國內外客戶提供優質的臨床開發服務!”

  

關于聯斯達

    聯斯達成立于2012年,是國內臨床研究現場管理組織(SMO)領導者之一。聯斯達與中國500多家國家藥物臨床試驗機構均達成了穩定的合作關系,總部設在北京,在南京設有分公司,并在上海、南京、廣州、杭州、成都、哈爾濱、合肥、武漢、西安等城市建立辦事處,覆蓋中國城市110+。公司至今服務項目達400+,85%為1類新藥和生物制品,擅長腫瘤、內分泌、心腦血管、抗感染和風濕免疫領域。

 

關于康龍化成

    康龍化成新藥技術股份有限公司(股票代碼:300759),成立于2004年,是國際領先的生命科學研發服務企業。經過十多年的快速發展,康龍化成打造了全方位的藥物研發一體化平臺,貫穿合成與合成及藥物化學、生物、藥物代謝及藥代動力學、藥理、藥物安全評價、放射標記化學、放射標記代謝、臨床藥理、臨床分析、原料藥和成品藥的工藝優化及生產、臨床CRO等領域??谍埢稍谥袊?、美國、英國均有運營實體,擁有6,800多名員工,一流的人才隊伍,高質量的研發服務,獲得了業界的廣泛認可,與北美、歐洲、日本和中國的各醫藥公司/機構保持著長期、穩固的合作關系。

詳情請訪問公司網站:www.pharmaron.com